Vhe T Ferrari, PA
Physician Assistant · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 3
Offices
3 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: California Pacific Medical Ctr-Davies Campus Hosp. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Vhe T Ferrari’s office at (415) 600-1020 to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
Original Medicare doctor bills
$21,618
Medicare paid this office $21,618 for 134 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 118 | $8,397 | $60 |
| Destruction of precancer skin growth, 1 growth | 73 | $3,915 | $50 |
| Return visit (30+ min) | 25 | $2,601 | $93 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $2,082 | $130 |
| Destruction of precancer skin growth, 2-14 growths | 64 | $2,039 | $5 |
See all 6 services
| Short return visit (20+ min) | 118 | $8,397 | $60 |
| Destruction of precancer skin growth, 1 growth | 73 | $3,915 | $50 |
| Return visit (30+ min) | 25 | $2,601 | $93 |
| Destruction of precancer skin growth, 15 or more growths | 14 | $2,082 | $130 |
| Destruction of precancer skin growth, 2-14 growths | 64 | $2,039 | $5 |
| Biopsy of related skin growth, first growth | 18 | $1,604 | $84 |
Procedures Medicare counted
| Removal of skin lesions | 139 | More than 77% of doctors who do this |
| Skin biopsy | 24 | More than 64% of doctors who do this |
Who their Medicare patients are
134 Original Medicare patients in 2024. Average age 76 · Women 46% · Health risk score 1.26. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 57% · Coronary heart disease 19% · Diabetes 16% · Cancer 16% · Atrial fibrillation 16% · Chronic kidney disease 13% · Depression 10%.
The office billed $104,911, Medicare allowed $31,485 and paid $21,618; for 679 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 134 | 679 | 76 | 1.26 | $104,911 | $21,618 |
| 2023 | 121 | 538 | 75 | 1.23 | $88,539 | $20,408 |
| 2022 | 68 | 248 | 75 | 1.26 | $41,337 | $9,338 |
| 2021 | 98 | 348 | 73 | 1.10 | $61,620 | $15,866 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Short return visit (20+ min) | 82 | $6,334 | $66 |
| Return visit (30+ min) | 49 | $4,804 | $92 |
| Biopsy of related skin growth, first growth | 32 | $3,014 | $89 |
| Destruction of precancer skin growth, 1 growth | 56 | $2,964 | $48 |
| Destruction of precancer skin growth, 2-14 growths | 49 | $1,606 | $6 |
2022: 5 services
| Return visit (30+ min) | 37 | $3,401 | $87 |
| Short return visit (20+ min) | 33 | $2,104 | $60 |
| Destruction of precancer skin growth, 1 growth | 23 | $1,108 | $46 |
| Biopsy of related skin growth, first growth | 12 | $1,086 | $84 |
| Destruction of precancer skin growth, 2-14 growths | 23 | $712 | $6 |
2021: 5 services
| Return visit (30+ min) | 57 | $6,652 | $101 |
| Short return visit (20+ min) | 47 | $3,154 | $66 |
| Destruction of precancer skin growth, 1 growth | 43 | $2,528 | $53 |
| Biopsy of related skin growth, first growth | 11 | $1,094 | $91 |
| Destruction of precancer skin growth, 2-14 growths | 29 | $913 | $6 |
Drugs they prescribed that Part D paid
$1,123
Pharmacies billed $1,123 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
37 generic and 19 brand-name prescriptions · $1,123 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ssd | 16 | $297 | $19 |
Year by year
| 2024 | 56 | 30 | None | 34% | $1,123 |
| 2023 | 38 | 24 | None | None | $1,435 |
| 2022 | 58 | 28 | 43% (25) | None | $2,536 |
| 2021 | 44 | 19 | None | None | $3,081 |
| 2020 | 48 | 28 | None | None | $1,317 |
| 2019 | 47 | 25 | None | None | $4,774 |
| 2018 | 39 | 20 | None | None | $12,861 |
| 2017 | 66 | 26 | None | None | $10,058 |
| 2016 | 662 | 87 | 65% (427) | 24% | $75,513 |
| 2015 | 550 | 91 | 57% (314) | 20% | $40,786 |
| 2014 | 175 | 45 | 49% (85) | 26% | $22,485 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2022: 1 drug
| Hydrocodone-Acetaminophen | 18 | $123 | $7 |
2021: 1 drug
| Clobetasol Propionate | 11 | $2,258 | $205 |
2019: 2 drugs
| Clobetasol Propionate | 11 | $4,019 | $365 |
| Triamcinolone Acetonide | 11 | $128 | $12 |
2018: 1 drug
| Clobetasol Propionate | 12 | $7,661 | $638 |
2017: 2 drugs
| Clobetasol Propionate | 23 | $6,935 | $302 |
| Gabapentin | 11 | $283 | $26 |
2016: 14 drugs
| Oxycontin | 50 | $34,963 | $699 |
| Lyrica | 16 | $5,457 | $341 |
| Morphine Sulfate Er | 36 | $4,548 | $126 |
| Hydrocodone-Acetaminophen | 120 | $4,414 | $37 |
| Duloxetine | 16 | $2,311 | $144 |
| Methadone | 80 | $2,039 | $25 |
| Fentanyl | 15 | $1,966 | $131 |
| Hydromorphone | 33 | $1,623 | $49 |
| Oxycodone | 39 | $1,403 | $36 |
| Oxycodone-Acetaminophen | 19 | $1,058 | $56 |
| Gabapentin | 40 | $768 | $19 |
| Ibuprofen | 21 | $168 | $8 |
| Zolpidem | 16 | $111 | $7 |
| Mirtazapine | 12 | $65 | $5 |
2015: 12 drugs
| Oxycontin | 29 | $14,642 | $505 |
| Morphine Sulfate Er | 52 | $6,381 | $123 |
| Hydrocodone-Acetaminophen | 96 | $3,260 | $34 |
| Methadone | 62 | $1,669 | $27 |
| Duloxetine | 11 | $1,473 | $134 |
| Gabapentin | 29 | $596 | $21 |
| Hydromorphone | 19 | $488 | $26 |
| Tizanidine | 20 | $416 | $21 |
| Zolpidem | 30 | $343 | $11 |
| Carisoprodol | 14 | $274 | $20 |
| Amitriptyline | 11 | $149 | $14 |
| Lorazepam | 15 | $93 | $6 |
2014: 3 drugs
| Morphine Sulfate Er | 13 | $1,546 | $119 |
| Methadone | 25 | $478 | $19 |
| Hydrocodone-Acetaminophen | 24 | $473 | $20 |
Money from drug and device companies
$177 in 2025
| 2025 | 2 | 2 | None | $177 |
| 2024 | 4 | 4 | None | $120 |
| 2023 | 2 | 2 | None | $61 |
| 2022 | 1 | 1 | None | $24 |
| 2021 | 4 | 6 | None | $154 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Libtayo | $123 | 1 payment
|
| Stryker | Audion Et Dilation System | $54 | 1 payment
|
See all 2 published payments
| Regeneron Healthcare Solutions | Meals · 2025-10-02 | Libtayo | $123 |
| Stryker | Meals · 2025-07-09 | Audion Et Dilation System | $54 |
See earlier years (2024, 2023, 2022, 2021)
2024: $120
| Merck Sharp & Dohme | Keytruda | $32 | 1 payment
|
| Kyowa Kirin | Poteligeo | $30 | 1 payment
|
| Hologic Sales and Service | Trunode | $29 | 1 payment
|
| Array Biopharma | Braftovi | $28 | 1 payment
|
2023: $61
| Regeneron Healthcare Solutions | Libtayo | $37 | 1 payment
|
| Tactile Systems Technology | Flexitouch Plus | $24 | 1 payment
|
2022: $24
| Merck Sharp & Dohme | Keytruda | $24 | 1 payment
|
2021: $154
| Lilly USA | Taltz | $87 | 3 payments
|
| LEO Pharma | Enstilar | $25 | 1 payment
|
| Genzyme | Dupixent | $21 | 1 payment
|
| Ortho Dermatologics a division of Bausch Health US | Duobrii | $21 | 1 payment
|
Professional record
- NPI
- 1619398914
- Licence
- CA PA51320
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1335 Stanford Ave, Emeryville, CA, 94608
- NPI first listed
- 2014-01-03
- NPI last updated
- 2014-11-18
This is when the NPI record was last certified, not a medical board exam.